Real-World Insights Into Prostate Cancer Management Using Electronic Health Record-Derived Data From the UK
Author(s)
Elsie Horne, PhD1, Patrycja Pluta, DVM, PhD2, Amit Samani, MD, PhD1, Arun Sujenthiran, MD1, Tamra Downing, MPH, MBA3, Deepika Singh, MBA3, Harlan Pittell, PhD3, Blythe Adamson, PhD, MPH3.
1Flatiron Health UK, London, United Kingdom, 2Flatiron Health Germany, Berlin, Germany, 3Flatiron Health, New York, NY, USA.
1Flatiron Health UK, London, United Kingdom, 2Flatiron Health Germany, Berlin, Germany, 3Flatiron Health, New York, NY, USA.
OBJECTIVES: Prostate cancer is one of the most prevalent cancers among men. High-quality, electronic health record (EHR)-derived datasets to learn about the experience of prostate cancer patients in the UK have previously been lacking. This study describes comprehensive, deidentified patient-level data from EHRs.
METHODS: The prostate cancer dataset was derived from the UK Flatiron Health Research Database, which includes data provided by patients and collected by the National Health Service as part of their care and support. The database includes structured and unstructured data, curated through technology-enabled abstraction and manual review. Variables include patient demographics, clinical characteristics, biomarker testing, treatment regimens, and mortality. Data quality and completeness were assessed to ensure fitness for research purposes.
RESULTS: The dataset included 2263 patients diagnosed with prostate cancer between 2011 and 2024. Of these, 491 (22%) had metastatic disease at diagnosis, and 194 (8.6%) progressed to metastatic disease during follow-up. Of the 316 patients with metastatic castration resistant disease, 44 (14%) were tested for BRCA mutations. Two hundred and seventy-two (25%) patients had first-line therapy with drugs other than LHRHa or 1st-generation antiandrogens. Amongst these, the most common first-line regimens were enzalutamide, abiraterone, and docetaxel (received by 41%, 19%, and 11% of patients, respectively). Prostate cancer-specific variables had high completeness, with 97% and 93% of patients having documented Gleason score and PSA at diagnosis, respectively.
CONCLUSIONS: The UK prostate cancer dataset offers a robust platform for generating actionable real-world evidence to inform health technology assessments and optimize prostate cancer management in the UK. The consistency in the data model and variable definitions between this and US EHR-derived data enables treatment pattern comparisons across the UK and US. By providing insights into real-world treatment patterns and biomarker testing, this dataset addresses critical gaps in the literature and supports evidence-based decision-making to benefit patients with prostate cancer.
METHODS: The prostate cancer dataset was derived from the UK Flatiron Health Research Database, which includes data provided by patients and collected by the National Health Service as part of their care and support. The database includes structured and unstructured data, curated through technology-enabled abstraction and manual review. Variables include patient demographics, clinical characteristics, biomarker testing, treatment regimens, and mortality. Data quality and completeness were assessed to ensure fitness for research purposes.
RESULTS: The dataset included 2263 patients diagnosed with prostate cancer between 2011 and 2024. Of these, 491 (22%) had metastatic disease at diagnosis, and 194 (8.6%) progressed to metastatic disease during follow-up. Of the 316 patients with metastatic castration resistant disease, 44 (14%) were tested for BRCA mutations. Two hundred and seventy-two (25%) patients had first-line therapy with drugs other than LHRHa or 1st-generation antiandrogens. Amongst these, the most common first-line regimens were enzalutamide, abiraterone, and docetaxel (received by 41%, 19%, and 11% of patients, respectively). Prostate cancer-specific variables had high completeness, with 97% and 93% of patients having documented Gleason score and PSA at diagnosis, respectively.
CONCLUSIONS: The UK prostate cancer dataset offers a robust platform for generating actionable real-world evidence to inform health technology assessments and optimize prostate cancer management in the UK. The consistency in the data model and variable definitions between this and US EHR-derived data enables treatment pattern comparisons across the UK and US. By providing insights into real-world treatment patterns and biomarker testing, this dataset addresses critical gaps in the literature and supports evidence-based decision-making to benefit patients with prostate cancer.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
RWD161
Topic
Real World Data & Information Systems
Topic Subcategory
Data Protection, Integrity, & Quality Assurance, Health & Insurance Records Systems
Disease
Oncology